GO
Loading...

FDA OK's New Version of Johnson & Johnson's Risperdal

Johnson & Johnson said U.S. regulators have approved the company's long-lasting version of its blockbuster schizophrenia treatment Risperdal.

The long-lasting version, Invega, or paliperidone, is a once-daily oral drug designed to deliver risperidone, the active ingredient in both Invega and Risperdal, through a technology that allows the drug to remain in the body over a longer period of time.

Invega, considered by some the most important drug in J&J's pipeline, will be marketed in the United States by the company's Janssen LP unit.

Symbol
Price
 
Change
%Change
JNJ
---

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video